Mérieux Equity Partners is a healthcare-specialized investment firm created in 2009, managing approximately €2 billion in assets under management across two dedicated platforms. The Innovation platform supports the development of innovative medical solutions from seed to Series B, investing €3–15 million per company in minority stakes across Europe. The Buyout platform invests €20–80 million in profitable, fast-growing healthcare companies, taking majority or minority positions. The firm operates from offices in Paris and Lyon with 18 investment professionals and has completed over 60 investments since inception. Mérieux Equity Partners is AMF-registered and manages third-party capital. Recent Innovation investments include SRTD Biotech (Germany, mRNA therapies), HighLife Medical (France, MedTech), and Ona Therapeutics (Spain, biopharmaceuticals).
Profile auto-generated from public sources — details unverified.
Jean-François Billet
Managing Partner - Head of Buyout
Thierry Chignon
Managing Partner – Head of Investor Relations Communication
Jaana Grüter
Partner
Theodor Wuppermann
Partner
Quentin de Labarre
Partner
Valérie Calenda
Managing Partner – Head of Innovation
François Rosenfeld
Partner
Yoann Bonnamour
Managing Director
Kristin Thompson
Director
Christine Demode
President, Head of operations